Alto Neuroscience, Inc. ("Alto") , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX100 to 800 Patients SHIELD II Enrolled more than ...

| With budget reconciliation right around the corner, different slices of the healthcare industry have made their views clear on issues like physician pay, ACA subsidies, telehealth flexibilities, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.